Suppr超能文献

乳腺癌肺转移患者手术获益不确定。

Uncertain benefit from surgery in patients with lung metastases from breast carcinoma.

作者信息

Planchard David, Soria Jean-Charles, Michiels Stefan, Grunenwald Dominique, Validire Pierre, Caliandro Raffaele, Girard Philippe, Le Chevalier Thierry

机构信息

Division of Cancer Medicine, Gustave Roussy Institut, Villejuif, France.

出版信息

Cancer. 2004 Jan 1;100(1):28-35. doi: 10.1002/cncr.11881.

Abstract

BACKGROUND

Isolated lung metastases have been reported to occur in 10-20% of all women with breast carcinoma. The authors described a series of patients who underwent surgery for lung metastases from breast carcinoma.

METHODS

They reviewed the files of 125 consecutive patients who underwent surgery with a curative intent for lung metastases from breast carcinoma between 1972 an 1998 at a single institution. Survival curves were plotted by the Kaplan-Meier method. Prognostic factors were identified using the log-rank test and a Cox proportional hazards model for univariate and multivariate analyses, respectively.

RESULTS

The median age at surgery was 53 years. There was a median of 1 resected metastasis (range, 1-16 resected metastases). The median size of the largest metastasis was 19 mm (range, 5-70 mm). The median disease-free interval (DFI) was 3 years. The median follow-up time after surgery was 8.5 years (range, 25 days to 22 years). The 3-year, 5-year, and 10-year probabilities of survival were 58% (95% confidence interval [95% CI], 49-67%), 45% (95% CI, 36-55%), and 30% (95% CI, 21-41%), respectively. The median survival time after surgery was 4.2 years. Complete resection was achieved in 96 patients. The quality of the resection (complete vs. incomplete) was not a statistically significant prognostic factor by univariate analysis and there was no significant difference between these two groups in terms of adjuvant postoperative therapy. The characteristics of the primary tumor and the number of metastases (one vs. two or more) had no detectable influence on survival. The size of the largest metastasis (> 20 mm or < or = 20 mm) and the DFI (< or = 3 years vs. > 3 years) were highly significant prognostic factors (P = 0.006 and P = 0.003, respectively). This was confirmed by multivariate analysis. Patients with a DFI < or = 3 years and/or the largest metastasis > 20 mm reportedly had a poor outcome (median survival, 2.6 years vs. 8.5 years for patients with none of these poor prognostic factors).

CONCLUSIONS

Resection of lung metastases from breast carcinoma was associated with a significant 5-year survival rate of 45%. Whether these encouraging findings resulted from the surgical procedure itself or the preoperative selection of patients remained uncertain. When surgery is considered in this setting, the size of the largest metastasis and the DFI should be taken into account.

摘要

背景

据报道,在所有乳腺癌女性患者中,孤立性肺转移的发生率为10% - 20%。作者描述了一系列接受乳腺癌肺转移手术的患者。

方法

他们回顾了1972年至1998年在同一机构接受根治性乳腺癌肺转移手术的125例连续患者的病历。采用Kaplan - Meier法绘制生存曲线。分别使用对数秩检验和Cox比例风险模型进行单因素和多因素分析来确定预后因素。

结果

手术时的中位年龄为53岁。切除转移灶的中位数为1个(范围为1 - 16个切除的转移灶)。最大转移灶的中位大小为19毫米(范围为5 - 70毫米)。中位无病间期(DFI)为3年。手术后的中位随访时间为8.5年(范围为25天至22年)。3年、5年和10年的生存率分别为58%(95%置信区间[95%CI],49 - 67%)、45%(95%CI,36 - 55%)和30%(95%CI,21 - 41%)。手术后的中位生存时间为4.2年。9六十例患者实现了完全切除。单因素分析显示,切除质量(完全切除与不完全切除)不是具有统计学意义的预后因素,且两组在术后辅助治疗方面无显著差异。原发肿瘤的特征和转移灶数量(1个与2个或更多)对生存无明显影响。最大转移灶的大小(>20毫米或≤20毫米)和DFI(≤3年与>3年)是高度显著的预后因素(分别为P = 0.006和P = 0.003)。多因素分析证实了这一点。据报道,DFI≤3年和/或最大转移灶>20毫米的患者预后较差(中位生存时间为2.6年,而无这些不良预后因素的患者为8.5年)。

结论

乳腺癌肺转移灶切除术后五年生存率达45%,具有显著意义。这些令人鼓舞的结果是源于手术本身还是术前患者选择尚不确定。在此情况下考虑手术时,应考虑最大转移灶的大小和DFI。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验